Compound nasal inhalation gel preparation for treating rhinitis

Abstract

The invention discloses a compound nasal inhalation gel preparation for treating rhinitis. The compound nasal inhalation gel preparation is prepared from, by weight, 0.2-0.3% of levofloxacin, 0.05-0.75% of hyaluronic acid, 0.025-0.05% of oxymetazoline, 0.8-1.0% of lysozyme, 0.025-0.05% of dexamethasone, 0.6-0.9% of sodium chloride, 8-10% of propylene glycol, 0.8-1.0% of Carbomer, 10-12% of glycerol and the balance purified water. The compound nasal inhalation gel preparation is convenient to use, becomes effective fast, and is free of toxic and side effects. Through scientific matching and reasonable compatibility of medicine materials, the content of effective constituents in the preparation is increased; furthermore, due to the fact that the gel preparation is sprayed onto the nasal mucosa, a unique treatment effect is realized through absorption of capillaries and the nasal mucosa based on the physiological characteristics of the nasal cavity, drug action time is prolonged, and a durable and stable treatment effect is realized.

Description

technical field [0001] The invention relates to the technical field of compound gel preparations, in particular to a compound nasal drop gel preparation for treating rhinitis. Background technique [0002] Chronic rhinitis and sinusitis are chronic inflammations characterized by hypertrophy and hyperplasia of the inferior turbinate caused by swelling of the nasal mucosa, and increased secretions in the nasal cavity. The clinical treatment of chronic rhinitis and sinusitis is mainly oral medicine and local application of nasal drops, and topical application Most of them use single drugs such as ephedrine and naphazoline, or use glucocorticoid nasal sprays such as Berkner and Fushuliang. The drug is single and the duration of the drug effect is short, and the therapeutic effect cannot be achieved permanently and stably. . [0003] "A compound pharmaceutical preparation for treating acute and chronic sinusitis, rhinitis and otitis media" invented by Gao Yundong and whose paten...

AI Technical Summary

Problems solved by technology

[0002] Chronic rhinitis and sinusitis are chronic inflammations characterized by hypertrophy and hyperplasia of the inferior turbinate caused by swelling of the nasal mucosa, and increased secretions in the nasal cavity. The clinical treatment of chronic rhinitis and sinusitis is mainly oral medicine and local application of nasal drops, and topical application Most of them use single drugs such as ephedrine and naphazoline, or use glucocorticoid nasal sprays such as Berkner and Fushuliang. The drug is single and the duration of the drug effect is short, and the therapeutic effect cannot be achieved permanently and stably.

[0003] "A compound pharmaceutical preparation for treating acute and chronic sinusitis, rhinitis and otitis media" invented by Gao Yundong and whose patent publication number is CN1277843A has been found to have the following disadvantages in clinical application: It is effective within a certain period of time but not lasting; ②The method of use is to let the patient lean back 80°, and put a small bench under the head and then put a small pillow, the method is too complicated; ③The time for the patient to lean back is 10 minutes. Long, it will cause headache, dizziness and other uncomfortable feelings in patients, especially for patients with cervical spondylosis, high blood pressure, and chronic cerebrovascular diseases. Long-term reclining will cause temporary insufficient blood supply to the brain; Use one bottle (4ml / branch) for the side nasal cavity, and 8ml for both sides, which is highly irritating to the nasal mucosa, and the medication cycle is long, 3 times a day, consecutively used for 2 months as a course of treatment, most patients cannot accept long-term use